Cargando…

Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases

Three open-source anti-kinetoplastid chemical boxes derived from a whole-cell phenotypic screening by GlaxoSmithKline (Tres Cantos Anti-Kinetoplastid Screening, TCAKS) were exploited for the discovery of a novel core structure inspiring new treatments of parasitic diseases targeting the trypansosmat...

Descripción completa

Detalles Bibliográficos
Autores principales: Santucci, Matteo, Luciani, Rosaria, Gianquinto, Eleonora, Pozzi, Cecilia, Pisa, Flavio di, dello Iacono, Lucia, Landi, Giacomo, Tagliazucchi, Lorenzo, Mangani, Stefano, Spyrakis, Francesca, Costi, Maria Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704748/
https://www.ncbi.nlm.nih.gov/pubmed/34959646
http://dx.doi.org/10.3390/ph14121246
_version_ 1784621781655486464
author Santucci, Matteo
Luciani, Rosaria
Gianquinto, Eleonora
Pozzi, Cecilia
Pisa, Flavio di
dello Iacono, Lucia
Landi, Giacomo
Tagliazucchi, Lorenzo
Mangani, Stefano
Spyrakis, Francesca
Costi, Maria Paola
author_facet Santucci, Matteo
Luciani, Rosaria
Gianquinto, Eleonora
Pozzi, Cecilia
Pisa, Flavio di
dello Iacono, Lucia
Landi, Giacomo
Tagliazucchi, Lorenzo
Mangani, Stefano
Spyrakis, Francesca
Costi, Maria Paola
author_sort Santucci, Matteo
collection PubMed
description Three open-source anti-kinetoplastid chemical boxes derived from a whole-cell phenotypic screening by GlaxoSmithKline (Tres Cantos Anti-Kinetoplastid Screening, TCAKS) were exploited for the discovery of a novel core structure inspiring new treatments of parasitic diseases targeting the trypansosmatidic pteridine reductase 1 (PTR1) and dihydrofolate reductase (DHFR) enzymes. In total, 592 compounds were tested through medium-throughput screening assays. A subset of 14 compounds successfully inhibited the enzyme activity in the low micromolar range of at least one of the enzymes from both Trypanosoma brucei and Lesihmania major parasites (pan-inhibitors), or from both PTR1 and DHFR-TS of the same parasite (dual inhibitors). Molecular docking studies of the protein–ligand interaction focused on new scaffolds not reproducing the well-known antifolate core clearly explaining the experimental data. TCMDC-143249, classified as a benzenesulfonamide derivative by the QikProp descriptor tool, showed selective inhibition of PTR1 and growth inhibition of the kinetoplastid parasites in the 5 μM range. In our work, we enlarged the biological profile of the GSK Kinetobox and identified new core structures inhibiting selectively PTR1, effective against the kinetoplastid infectious protozoans. In perspective, we foresee the development of selective PTR1 and DHFR inhibitors for studies of drug combinations.
format Online
Article
Text
id pubmed-8704748
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87047482021-12-25 Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases Santucci, Matteo Luciani, Rosaria Gianquinto, Eleonora Pozzi, Cecilia Pisa, Flavio di dello Iacono, Lucia Landi, Giacomo Tagliazucchi, Lorenzo Mangani, Stefano Spyrakis, Francesca Costi, Maria Paola Pharmaceuticals (Basel) Article Three open-source anti-kinetoplastid chemical boxes derived from a whole-cell phenotypic screening by GlaxoSmithKline (Tres Cantos Anti-Kinetoplastid Screening, TCAKS) were exploited for the discovery of a novel core structure inspiring new treatments of parasitic diseases targeting the trypansosmatidic pteridine reductase 1 (PTR1) and dihydrofolate reductase (DHFR) enzymes. In total, 592 compounds were tested through medium-throughput screening assays. A subset of 14 compounds successfully inhibited the enzyme activity in the low micromolar range of at least one of the enzymes from both Trypanosoma brucei and Lesihmania major parasites (pan-inhibitors), or from both PTR1 and DHFR-TS of the same parasite (dual inhibitors). Molecular docking studies of the protein–ligand interaction focused on new scaffolds not reproducing the well-known antifolate core clearly explaining the experimental data. TCMDC-143249, classified as a benzenesulfonamide derivative by the QikProp descriptor tool, showed selective inhibition of PTR1 and growth inhibition of the kinetoplastid parasites in the 5 μM range. In our work, we enlarged the biological profile of the GSK Kinetobox and identified new core structures inhibiting selectively PTR1, effective against the kinetoplastid infectious protozoans. In perspective, we foresee the development of selective PTR1 and DHFR inhibitors for studies of drug combinations. MDPI 2021-11-30 /pmc/articles/PMC8704748/ /pubmed/34959646 http://dx.doi.org/10.3390/ph14121246 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Santucci, Matteo
Luciani, Rosaria
Gianquinto, Eleonora
Pozzi, Cecilia
Pisa, Flavio di
dello Iacono, Lucia
Landi, Giacomo
Tagliazucchi, Lorenzo
Mangani, Stefano
Spyrakis, Francesca
Costi, Maria Paola
Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title_full Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title_fullStr Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title_full_unstemmed Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title_short Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases
title_sort repurposing the trypanosomatidic gsk kinetobox for the inhibition of parasitic pteridine and dihydrofolate reductases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704748/
https://www.ncbi.nlm.nih.gov/pubmed/34959646
http://dx.doi.org/10.3390/ph14121246
work_keys_str_mv AT santuccimatteo repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT lucianirosaria repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT gianquintoeleonora repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT pozzicecilia repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT pisaflaviodi repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT delloiaconolucia repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT landigiacomo repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT tagliazucchilorenzo repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT manganistefano repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT spyrakisfrancesca repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases
AT costimariapaola repurposingthetrypanosomatidicgskkinetoboxfortheinhibitionofparasiticpteridineanddihydrofolatereductases